Abstract 615P
Background
Vascular endothelial growth factor receptor (VEGFR) inhibitors have demonstrated promising activity for recurrent and unresectable osteosarcoma. However, the use of VEGFR inhibitor for pulmonary metastatic osteosarcoma to improve resectability and postoperative outcome remains unexplored.
Methods
We did a single-arm phase 2 trial investigating the efficacy of adding anti-angiogenics to chemo for resectable pulmonary metastases (PMs) of osteosarcoma. Pts received VEGFR inhibitor Apatinib plus gemcitabine-docetaxel for 3 cycles pre- and 4 cycles post-metastasectomy, followed by Apatinib monotherapy maintenance until disease progression or unacceptable toxicities. Our primary endpoint was 12-month progression-free rate (12m-PFR) with a historical control of <30%. The primary endpoint would be met if ≥17 out of 39 evaluable pts were considered non-progression, corresponding to a pre-specified 12m-PFR of 50%.
Results
We enrolled 43 pts from Mar 2019 to Nov 2022 in this study, with 23 (54%) having ≥4 PMs, 12 (28%) having ≥10 PMs, and 24 (56%) having bilateral PMs. Extra tiny PMs were commonly detected and resected during surgical exploration. 39/43 pts (91%) finished their surgical procedures as planned, while 1 pt encountered tumor progression before metastasectomy and 3 failed to undergo the 2nd-stage metastasectomy after the 1st stage. Two pts were excluded from efficacy analysis due to major protocol violations. Of the remaining 41 pts, tumor volume reduction was seen in 30 (73.2%) pts before surgery, and 18 of the first 39 evaluable pts were progression-free at 12m (primary endpoint met). In the safety analysis (43 pts), ≥grade 3 toxicities were noticed in 29(67%) pts. One of the 15 deaths was due to post-operative complications and the remaining (14/15) due to tumor progression. The most common grade 3–4 toxicies were thrombocytopenia (26%), proteinuria (16%), anemia (14%), granulocytopenia(12%), pain(9.3%), pneumothorax(9.3%). Of note, only 2 ≥grade 3 postoperative wound problems following VEGFR inhibitor were observed.
Conclusions
Our study demonstrated a potential activity of combining Apatinib plus chemotherapy with metastasectomy for treating pulmonary metastatic osteosarcoma.
Clinical trial identification
NCT03742193.
Editorial acknowledgement
We are wholeheartedly gratefull to all participants and their parents in this study.
Legal entity responsible for the study
Ruijin Hospital, Shanghai Jiaotong University.
Funding
Shanghai Municipal Health Commission (grant No. 202140124) National Science Foundation of China (grant No. 82141116) Natural Science Foundation of Shanghai (grant No. 20ZR1434000).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
297P - The utilization rate of radiotherapy and chemotherapy for cervical cancer in Indonesia: Optimal versus actual, how far the gap?
Presenter: Charity Kotambunan
Session: Poster Display
Resources:
Abstract
298P - Managing locally advanced cervical cancer: Insights from a tertiary care center and a 3-year follow-up on outcomes
Presenter: Ambedkar Yadala
Session: Poster Display
Resources:
Abstract
299P - Sexual dysfunction assessment in longterm survivors of carcinoma cervix using LENT SOMA scale
Presenter: Niharika Sethi
Session: Poster Display
Resources:
Abstract
300P - Assessing ovarian function in Vietnamese cervical cancer patients who underwent ovary transposition prior to pelvic radiation therapy
Presenter: Cuong Nguyen
Session: Poster Display
Resources:
Abstract
301P - Correlation between cervical cancer recurrence after radiation therapy and vaginal microbiome
Presenter: Xiaoxian Xu
Session: Poster Display
Resources:
Abstract
302P - Expression of ERCC4 gene and its correlation with clinical and pathological parameters in cervical cancer
Presenter: Himanshu Mishra
Session: Poster Display
Resources:
Abstract
303P - Prognostic value of body composition and systemic inflammatory markers in patients with locally advanced cervical cancer following chemoradiotherapy
Presenter: Hui Guo
Session: Poster Display
Resources:
Abstract
305P - A real-world multicenter cohort study of lenvatinib (LEN) plus pembrolizumab (PEM) in Japanese patients with endometrial cancer: Interim analysis of GOGO-EM4 study
Presenter: Yoshikazu Nagase
Session: Poster Display
Resources:
Abstract
306P - Adjuvant treatment and impact on relapse in stage IA uterine papillary serous and clear cell carcinomas: A single center retrospective study
Presenter: Sachin Khurana
Session: Poster Display
Resources:
Abstract
307P - Hormonal therapy vs combination chemotherapy in metastatic leiomyosarcomas: A systematic review
Presenter: Patricia Angel
Session: Poster Display
Resources:
Abstract